NO323320B1 - Medikament egnet til behandling av ondartede tumorer - Google Patents
Medikament egnet til behandling av ondartede tumorer Download PDFInfo
- Publication number
- NO323320B1 NO323320B1 NO20021932A NO20021932A NO323320B1 NO 323320 B1 NO323320 B1 NO 323320B1 NO 20021932 A NO20021932 A NO 20021932A NO 20021932 A NO20021932 A NO 20021932A NO 323320 B1 NO323320 B1 NO 323320B1
- Authority
- NO
- Norway
- Prior art keywords
- methyl
- quinoline
- oxo
- carboxamide
- dihydro
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title claims description 12
- 201000011510 cancer Diseases 0.000 title abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 76
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 239000001257 hydrogen Substances 0.000 claims description 57
- 229910052739 hydrogen Inorganic materials 0.000 claims description 57
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 41
- 150000002431 hydrogen Chemical class 0.000 claims description 29
- 239000000460 chlorine Chemical group 0.000 claims description 28
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 27
- 229910052801 chlorine Inorganic materials 0.000 claims description 27
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 25
- 239000011737 fluorine Chemical group 0.000 claims description 25
- 229910052731 fluorine Inorganic materials 0.000 claims description 25
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 24
- 206010060862 Prostate cancer Diseases 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- -1 n-butyl-iso-butyl Chemical group 0.000 claims description 18
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 15
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 12
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 12
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 7
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 6
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- XWNYCYLXNGLYKJ-UHFFFAOYSA-N 4-amino-n,1,5-trimethyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound NC=1C2=C(C)C=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 XWNYCYLXNGLYKJ-UHFFFAOYSA-N 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- QJHXVIRCPDYURC-UHFFFAOYSA-N 5-(dimethylamino)-n-ethyl-4-hydroxy-1-methyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound OC=1C2=C(N(C)C)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 QJHXVIRCPDYURC-UHFFFAOYSA-N 0.000 claims description 4
- AUKZBVKADNQWSZ-UHFFFAOYSA-N 5-methoxy-n,1-dimethyl-4-(methylamino)-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC(OC)=C2C(NC)=C1C(=O)N(C)C1=CC=CC=C1 AUKZBVKADNQWSZ-UHFFFAOYSA-N 0.000 claims description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 150000001767 cationic compounds Chemical class 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 229960002887 deanol Drugs 0.000 claims description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 229910001411 inorganic cation Inorganic materials 0.000 claims description 4
- XMSZANIMCDLNKA-UHFFFAOYSA-N methyl hypofluorite Chemical group COF XMSZANIMCDLNKA-UHFFFAOYSA-N 0.000 claims description 4
- 150000002892 organic cations Chemical class 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- OJWYYSVOSNWCCE-UHFFFAOYSA-N 2-methoxyethyl hypofluorite Chemical compound COCCOF OJWYYSVOSNWCCE-UHFFFAOYSA-N 0.000 claims description 3
- CFEOYAOYSLOMIN-UHFFFAOYSA-N 4-amino-5-methoxy-n,1-dimethyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound NC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 CFEOYAOYSLOMIN-UHFFFAOYSA-N 0.000 claims description 3
- WVMIJXKUTBQGAK-UHFFFAOYSA-N 5-chloro-n-(4-chlorophenyl)-4-hydroxy-n,1-dimethyl-2-oxoquinoline-3-carboxamide Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(Cl)C=C1 WVMIJXKUTBQGAK-UHFFFAOYSA-N 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- UCFFGYASXIPWPD-UHFFFAOYSA-N methyl hypochlorite Chemical group COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 claims description 3
- OJYGICSISOLYTH-UHFFFAOYSA-N n,1,5-trimethyl-4-(methylamino)-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC(C)=C2C(NC)=C1C(=O)N(C)C1=CC=CC=C1 OJYGICSISOLYTH-UHFFFAOYSA-N 0.000 claims description 3
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 claims description 3
- VFKZOVNOHFQLGN-UHFFFAOYSA-N 4-chloro-2-oxo-1h-quinoline-3-carboxamide Chemical class C1=CC=C2NC(=O)C(C(=O)N)=C(Cl)C2=C1 VFKZOVNOHFQLGN-UHFFFAOYSA-N 0.000 claims description 2
- HNVINGXDDMWQLU-UHFFFAOYSA-N 5-(dimethylamino)-4-hydroxy-n-(4-methoxyphenyl)-n,1-dimethyl-2-oxoquinoline-3-carboxamide Chemical compound C1=CC(OC)=CC=C1N(C)C(=O)C1=C(O)C2=C(N(C)C)C=CC=C2N(C)C1=O HNVINGXDDMWQLU-UHFFFAOYSA-N 0.000 claims description 2
- NHDURIXSKYSQOE-UHFFFAOYSA-N 5-bromo-n-ethyl-4-hydroxy-1-methyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound OC=1C2=C(Br)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 NHDURIXSKYSQOE-UHFFFAOYSA-N 0.000 claims description 2
- ODHLTMOBLGQWPW-UHFFFAOYSA-N 5-chloro-n-(2,4-difluorophenyl)-4-hydroxy-n,1-dimethyl-2-oxoquinoline-3-carboxamide Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(F)C=C1F ODHLTMOBLGQWPW-UHFFFAOYSA-N 0.000 claims description 2
- FUDWAPGUYBYXQF-UHFFFAOYSA-N 5-chloro-n-(2,5-difluorophenyl)-4-hydroxy-n,1-dimethyl-2-oxoquinoline-3-carboxamide Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC(F)=CC=C1F FUDWAPGUYBYXQF-UHFFFAOYSA-N 0.000 claims description 2
- NBBLDIJJFFEJGC-UHFFFAOYSA-N 5-chloro-n-ethyl-n-(3-fluorophenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC(F)=C1 NBBLDIJJFFEJGC-UHFFFAOYSA-N 0.000 claims description 2
- RJSYPKWVIJGNLO-UHFFFAOYSA-N CCOClOC Chemical group CCOClOC RJSYPKWVIJGNLO-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- DIKSYHCCYVYKRO-UHFFFAOYSA-N n,5-diethyl-4-hydroxy-1-methyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound OC=1C2=C(CC)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 DIKSYHCCYVYKRO-UHFFFAOYSA-N 0.000 claims description 2
- GFRPIRITMNPYQF-UHFFFAOYSA-N n,5-diethyl-4-hydroxy-n-(3-methoxyphenyl)-1-methyl-2-oxoquinoline-3-carboxamide Chemical compound OC=1C2=C(CC)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC(OC)=C1 GFRPIRITMNPYQF-UHFFFAOYSA-N 0.000 claims description 2
- KYLCUIKSNXNVOO-UHFFFAOYSA-N n-(2,4-difluorophenyl)-4-hydroxy-5-methoxy-n,1-dimethyl-2-oxoquinoline-3-carboxamide Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(F)C=C1F KYLCUIKSNXNVOO-UHFFFAOYSA-N 0.000 claims description 2
- IRBHLTMIYWJTOQ-UHFFFAOYSA-N n-(2,4-difluorophenyl)-5-ethyl-4-hydroxy-n,1-dimethyl-2-oxoquinoline-3-carboxamide Chemical compound OC=1C=2C(CC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(F)C=C1F IRBHLTMIYWJTOQ-UHFFFAOYSA-N 0.000 claims description 2
- GUSDWFSFDMALPX-UHFFFAOYSA-N n-(2,4-difluorophenyl)-9-hydroxy-n,6-dimethyl-7-oxo-[1,3]dioxolo[4,5-f]quinoline-8-carboxamide Chemical compound OC=1C2=C3OCOC3=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(F)C=C1F GUSDWFSFDMALPX-UHFFFAOYSA-N 0.000 claims description 2
- MJEGPKLIGUTZKB-UHFFFAOYSA-N n-(2,5-difluorophenyl)-4-hydroxy-5-methoxy-n,1-dimethyl-2-oxoquinoline-3-carboxamide Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC(F)=CC=C1F MJEGPKLIGUTZKB-UHFFFAOYSA-N 0.000 claims description 2
- NNDZSFODGTZLGR-UHFFFAOYSA-N n-ethyl-4-hydroxy-1,5-dimethyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound OC=1C2=C(C)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 NNDZSFODGTZLGR-UHFFFAOYSA-N 0.000 claims description 2
- DVCXLZGKWGUOIH-UHFFFAOYSA-N n-ethyl-4-hydroxy-5-methoxy-1-methyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound OC=1C2=C(OC)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 DVCXLZGKWGUOIH-UHFFFAOYSA-N 0.000 claims description 2
- UODJYZJOKPIRKX-UHFFFAOYSA-N n-ethyl-9-hydroxy-6-methyl-7-oxo-n-phenyl-[1,3]dioxolo[4,5-f]quinoline-8-carboxamide Chemical compound OC=1C2=C3OCOC3=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 UODJYZJOKPIRKX-UHFFFAOYSA-N 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- ONDYALNGTUAJDX-UHFFFAOYSA-N tasquinimod Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 ONDYALNGTUAJDX-UHFFFAOYSA-N 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- USCADHFHQOZWAP-UHFFFAOYSA-N ethoxy-fluoro-methoxy-lambda3-chlorane Chemical compound COCl(F)OCC USCADHFHQOZWAP-UHFFFAOYSA-N 0.000 claims 1
- LAMXAYAGHJBCPT-UHFFFAOYSA-N n-(4-chlorophenyl)-n-ethyl-4-hydroxy-1,5-dimethyl-2-oxoquinoline-3-carboxamide Chemical compound OC=1C2=C(C)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=C(Cl)C=C1 LAMXAYAGHJBCPT-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 21
- 230000003287 optical effect Effects 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 26
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 238000005481 NMR spectroscopy Methods 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 11
- 229960003522 roquinimex Drugs 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 7
- 150000003248 quinolines Chemical class 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000012876 carrier material Substances 0.000 description 4
- 238000007273 lactonization reaction Methods 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- RULWBFLPUAFFGY-UHFFFAOYSA-N 2-(hydroxymethyl)benzamide Chemical class NC(=O)C1=CC=CC=C1CO RULWBFLPUAFFGY-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000005951 type IV hypersensitivity Effects 0.000 description 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 2
- YWJVOCIMIARJLF-UHFFFAOYSA-N 4-chloro-n,1,5-trimethyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound ClC=1C2=C(C)C=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 YWJVOCIMIARJLF-UHFFFAOYSA-N 0.000 description 2
- BJRSGCGGEWQAJG-UHFFFAOYSA-N 5-chloro-4-hydroxy-n,1-dimethyl-2-oxo-n-(4-phenylphenyl)quinoline-3-carboxamide Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(C)C(C=C1)=CC=C1C1=CC=CC=C1 BJRSGCGGEWQAJG-UHFFFAOYSA-N 0.000 description 2
- LMFXHIRZQCARKD-UHFFFAOYSA-N 5-chloro-n,1-dimethyl-4-(methylamino)-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC(Cl)=C2C(NC)=C1C(=O)N(C)C1=CC=CC=C1 LMFXHIRZQCARKD-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- OJGMBLNIHDZDGS-UHFFFAOYSA-N N-Ethylaniline Chemical compound CCNC1=CC=CC=C1 OJGMBLNIHDZDGS-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000002587 enol group Chemical group 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- KFYPWXUWAUYKHF-UHFFFAOYSA-N ethyl 5-(dimethylamino)-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)OCC)=C(O)C2=C1N(C)C KFYPWXUWAUYKHF-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- BLTDCIWCFCUQCB-UHFFFAOYSA-N quinoline-3-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CN=C21 BLTDCIWCFCUQCB-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ACOQDKIUGAKZTC-UHFFFAOYSA-N 2,6-bis(dimethylamino)benzonitrile Chemical compound CN(C)C1=CC=CC(N(C)C)=C1C#N ACOQDKIUGAKZTC-UHFFFAOYSA-N 0.000 description 1
- BNBRIFIJRKJGEI-UHFFFAOYSA-N 2,6-difluorobenzonitrile Chemical compound FC1=CC=CC(F)=C1C#N BNBRIFIJRKJGEI-UHFFFAOYSA-N 0.000 description 1
- DKNQSCLMUOGGRN-UHFFFAOYSA-N 2-(dimethylamino)-6-(methylamino)benzoic acid Chemical compound CNC1=CC=CC(N(C)C)=C1C(O)=O DKNQSCLMUOGGRN-UHFFFAOYSA-N 0.000 description 1
- IBAGBHFAJNYENY-UHFFFAOYSA-N 2-(dimethylamino)-6-(methylamino)benzonitrile Chemical compound CNC1=CC=CC(N(C)C)=C1C#N IBAGBHFAJNYENY-UHFFFAOYSA-N 0.000 description 1
- WWNKVUULRIWDJZ-UHFFFAOYSA-N 2-(dimethylamino)-6-fluorobenzonitrile Chemical compound CN(C)C1=CC=CC(F)=C1C#N WWNKVUULRIWDJZ-UHFFFAOYSA-N 0.000 description 1
- IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 1
- WFRGNPYTRJWFIV-UHFFFAOYSA-N 4,5-dichloro-n,1-dimethyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound ClC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 WFRGNPYTRJWFIV-UHFFFAOYSA-N 0.000 description 1
- JRUVVBSURPXORX-UHFFFAOYSA-N 4-(4-chloroanilino)-n,1-dimethyl-2-oxo-n-phenyl-5-(trifluoromethyl)quinoline-3-carboxamide Chemical compound C=1C=CC=CC=1N(C)C(=O)C(C(N(C)C1=CC=CC(=C11)C(F)(F)F)=O)=C1NC1=CC=C(Cl)C=C1 JRUVVBSURPXORX-UHFFFAOYSA-N 0.000 description 1
- NAUWVBKBJYELQN-UHFFFAOYSA-N 4-(benzylamino)-5-methoxy-n,1-dimethyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound C=1C=CC=CC=1CNC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 NAUWVBKBJYELQN-UHFFFAOYSA-N 0.000 description 1
- OPOZVRLZTNLPEX-UHFFFAOYSA-N 4-(dimethylamino)-5-methoxy-n,1-dimethyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound CN(C)C=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 OPOZVRLZTNLPEX-UHFFFAOYSA-N 0.000 description 1
- UALASPRERBSCDU-UHFFFAOYSA-N 4-(dimethylamino)-n,1,5-trimethyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC(C)=C2C(N(C)C)=C1C(=O)N(C)C1=CC=CC=C1 UALASPRERBSCDU-UHFFFAOYSA-N 0.000 description 1
- ZNRGDEGLQRUFDO-UHFFFAOYSA-N 4-(dimethylamino)-n,1-dimethyl-2-oxo-n-[4-(trifluoromethyl)phenyl]quinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC=C2C(N(C)C)=C1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 ZNRGDEGLQRUFDO-UHFFFAOYSA-N 0.000 description 1
- VANGGQUQLLNHQN-UHFFFAOYSA-N 4-(dimethylamino)-n,1-dimethyl-2-oxo-n-phenyl-5-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC(C(F)(F)F)=C2C(N(C)C)=C1C(=O)N(C)C1=CC=CC=C1 VANGGQUQLLNHQN-UHFFFAOYSA-N 0.000 description 1
- FZSSUQAKGYIIPU-UHFFFAOYSA-N 4-(dimethylamino)-n-ethyl-5-methoxy-1-methyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound CN(C)C=1C2=C(OC)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 FZSSUQAKGYIIPU-UHFFFAOYSA-N 0.000 description 1
- JYUJBAVRXWYCHG-UHFFFAOYSA-N 4-(ethylamino)-n,1,5-trimethyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC(C)=C2C(NCC)=C1C(=O)N(C)C1=CC=CC=C1 JYUJBAVRXWYCHG-UHFFFAOYSA-N 0.000 description 1
- XRAUMSZKCGKYER-UHFFFAOYSA-N 4-amino-5-chloro-n,1-dimethyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound NC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 XRAUMSZKCGKYER-UHFFFAOYSA-N 0.000 description 1
- MDQPBNVHWFSESU-UHFFFAOYSA-N 4-amino-n,1-dimethyl-2-oxo-n-[4-(trifluoromethyl)phenyl]quinoline-3-carboxamide Chemical compound NC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 MDQPBNVHWFSESU-UHFFFAOYSA-N 0.000 description 1
- HNXHHPUDXFCAAW-UHFFFAOYSA-N 4-hydroxy-n,1,5-trimethyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound OC=1C2=C(C)C=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 HNXHHPUDXFCAAW-UHFFFAOYSA-N 0.000 description 1
- BRIPFWASSPEAAQ-UHFFFAOYSA-N 5-bromo-n-ethyl-4-(ethylamino)-1-methyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC(Br)=C2C(NCC)=C1C(=O)N(CC)C1=CC=CC=C1 BRIPFWASSPEAAQ-UHFFFAOYSA-N 0.000 description 1
- HNKBKNNTMUTACU-UHFFFAOYSA-N 5-chloro-1-methyl-4-(methylamino)-2-oxo-n-phenyl-n-propylquinoline-3-carboxamide Chemical compound CNC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CCC)C1=CC=CC=C1 HNKBKNNTMUTACU-UHFFFAOYSA-N 0.000 description 1
- LABFTJYSYDRSJD-UHFFFAOYSA-N 5-chloro-4-(cyclopentylamino)-n-ethyl-1-methyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound C=1C=CC=CC=1N(CC)C(=O)C(C(N(C)C1=CC=CC(Cl)=C11)=O)=C1NC1CCCC1 LABFTJYSYDRSJD-UHFFFAOYSA-N 0.000 description 1
- HCBPMEYLCVLAJL-UHFFFAOYSA-N 5-chloro-4-(dimethylamino)-n,1-dimethyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC(Cl)=C2C(N(C)C)=C1C(=O)N(C)C1=CC=CC=C1 HCBPMEYLCVLAJL-UHFFFAOYSA-N 0.000 description 1
- FTBWKSJUFWRKGL-UHFFFAOYSA-N 5-chloro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxylic acid Chemical compound C1=CC(Cl)=C2C(O)=C(C(O)=O)C(=O)N(C)C2=C1 FTBWKSJUFWRKGL-UHFFFAOYSA-N 0.000 description 1
- SGNMNQCEISCAHF-UHFFFAOYSA-N 5-chloro-4-hydroxy-n,1-dimethyl-n-(4-methylphenyl)-2-oxoquinoline-3-carboxamide Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C)C=C1 SGNMNQCEISCAHF-UHFFFAOYSA-N 0.000 description 1
- JTLBKLOLMHZTDZ-UHFFFAOYSA-N 5-chloro-n-ethyl-1-methyl-4-(methylamino)-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound CNC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 JTLBKLOLMHZTDZ-UHFFFAOYSA-N 0.000 description 1
- DEGLQHFLAYKBNB-UHFFFAOYSA-N 5-ethyl-n,1-dimethyl-2-oxo-n-phenyl-4-piperidin-1-ylquinoline-3-carboxamide Chemical compound C1CCCCN1C=1C=2C(CC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 DEGLQHFLAYKBNB-UHFFFAOYSA-N 0.000 description 1
- GRUMANVWTCUZMN-UHFFFAOYSA-N 6-(dimethylamino)-1-methyl-3,1-benzoxazine-2,4-dione Chemical compound CN1C(=O)OC(=O)C2=CC(N(C)C)=CC=C21 GRUMANVWTCUZMN-UHFFFAOYSA-N 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 230000006181 N-acylation Effects 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZIQCCIAIROIHHR-UHFFFAOYSA-N benzene;boric acid Chemical compound OB(O)O.C1=CC=CC=C1 ZIQCCIAIROIHHR-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- RRIWSRWITVRKIJ-UHFFFAOYSA-N methyl 2-(dimethylamino)-6-(methylamino)benzoate Chemical compound CNC1=CC=CC(N(C)C)=C1C(=O)OC RRIWSRWITVRKIJ-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- OGOMYTRMAKBQQC-UHFFFAOYSA-N n,1-dimethyl-4-(methylamino)-2-oxo-n-[4-(trifluoromethyl)phenyl]quinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC=C2C(NC)=C1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 OGOMYTRMAKBQQC-UHFFFAOYSA-N 0.000 description 1
- USPKMDOCPGQQEY-UHFFFAOYSA-N n,5-diethyl-4-(ethylamino)-1-methyl-2-oxo-n-phenylquinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC(CC)=C2C(NCC)=C1C(=O)N(CC)C1=CC=CC=C1 USPKMDOCPGQQEY-UHFFFAOYSA-N 0.000 description 1
- JBJSLQDATNOKEK-UHFFFAOYSA-N n-(4-bromophenyl)-2,2,2-trifluoro-n-methylacetamide Chemical compound FC(F)(F)C(=O)N(C)C1=CC=C(Br)C=C1 JBJSLQDATNOKEK-UHFFFAOYSA-N 0.000 description 1
- XQRPKGVLTTYJTM-UHFFFAOYSA-N n-(4-chlorophenyl)-4-hydroxy-n,1,5-trimethyl-2-oxoquinoline-3-carboxamide Chemical compound OC=1C2=C(C)C=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(Cl)C=C1 XQRPKGVLTTYJTM-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16140799P | 1999-10-25 | 1999-10-25 | |
| SE9903838A SE9903838D0 (sv) | 1999-10-25 | 1999-10-25 | Novel compounds |
| US21281600P | 2000-06-21 | 2000-06-21 | |
| SE0002320A SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Malignant tumors |
| PCT/SE2000/002055 WO2001030758A1 (en) | 1999-10-25 | 2000-10-24 | Drugs for the treatment of malignant tumours |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20021932D0 NO20021932D0 (no) | 2002-04-24 |
| NO20021932L NO20021932L (no) | 2002-06-21 |
| NO323320B1 true NO323320B1 (no) | 2007-03-12 |
Family
ID=27484521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20021932A NO323320B1 (no) | 1999-10-25 | 2002-04-24 | Medikament egnet til behandling av ondartede tumorer |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1224172B1 (de) |
| JP (1) | JP3950337B2 (de) |
| KR (2) | KR100597938B1 (de) |
| AT (1) | ATE358668T1 (de) |
| AU (1) | AU775057B2 (de) |
| CA (1) | CA2386775C (de) |
| CZ (1) | CZ298534B6 (de) |
| DE (1) | DE60034240T2 (de) |
| DK (1) | DK1224172T3 (de) |
| EE (1) | EE200200207A (de) |
| ES (1) | ES2280258T3 (de) |
| HK (1) | HK1049830A1 (de) |
| HR (1) | HRP20020353A2 (de) |
| HU (1) | HU229072B1 (de) |
| IL (2) | IL148782A0 (de) |
| IS (1) | IS2750B (de) |
| NO (1) | NO323320B1 (de) |
| NZ (1) | NZ518296A (de) |
| SE (1) | SE0002320D0 (de) |
| UA (1) | UA73748C2 (de) |
| WO (1) | WO2001030758A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
| NZ587549A (en) | 2004-06-24 | 2012-10-26 | Vertex Pharma | 6-Amino-indole derivatives and processes for their preparation |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| KR101440982B1 (ko) | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
| CA2635581C (en) | 2005-12-28 | 2017-02-28 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US7989473B2 (en) | 2006-06-12 | 2011-08-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| KR100916160B1 (ko) * | 2007-02-21 | 2009-09-08 | (주)바이오버드 | 약제학적 항암 조성물 |
| EP2065380A1 (de) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridonamid-Derivate als Focal-Adhesion-Kinase (FAK) Hemmer und deren Verwendung zur Behandlung von Krebs |
| US8178127B2 (en) | 2007-12-20 | 2012-05-15 | Teva Pharmaceuticals Industries, Ltd. | Stable laquinimod preparations |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| JP2012502038A (ja) | 2008-09-03 | 2012-01-26 | テバ ファーマシューティカル インダストリーズ リミティド | 免疫機能の２−オキソ−１，２−ジヒドロ−キノリンモジュレーター |
| PL2408750T3 (pl) | 2009-03-20 | 2016-02-29 | Vertex Pharma | Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy |
| EP2627638B1 (de) * | 2010-10-14 | 2017-07-12 | Immunahr AB | 1,2-dihydro-4-hydroxy-2-oxo-chinolin-3-carboxanilide als ahr-aktivatoren |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| EP2537517A1 (de) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-angereichertes 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluor-methyl)phenyl]-1,2-dihydrochinolin-3-carboxamid |
| AU2013226076B2 (en) | 2012-02-27 | 2017-11-16 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
| HK1215210A1 (zh) * | 2012-11-07 | 2016-08-19 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德胺盐 |
| US9233927B2 (en) | 2013-03-14 | 2016-01-12 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| EA030948B1 (ru) * | 2014-09-23 | 2018-10-31 | Эктив Байотек Аб | Хинолинкарбоксамиды для применения в лечении множественной миеломы |
| KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
| EA031643B1 (ru) | 2014-11-19 | 2019-01-31 | Эктив Байотек Аб | Применение тасквинимода для лечения острого лимфобластного лейкоза и острого миелоидного лейкоза |
| JP7223998B2 (ja) | 2017-10-13 | 2023-02-17 | 小野薬品工業株式会社 | Ａｘｌ阻害剤を有効成分として含む固形がん治療剤 |
| AU2020393384A1 (en) * | 2019-11-28 | 2022-06-09 | Bayer Aktiengesellschaft | Substituted aminoquinolones as DGKalpha inhibitors for immune activation |
| US20230085883A1 (en) | 2020-03-03 | 2023-03-23 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| WO2021237112A1 (en) * | 2020-05-21 | 2021-11-25 | Stemsynergy Therapeutics, Inc. | Notch inhibitors and uses thereof |
| US20240091215A1 (en) | 2021-01-18 | 2024-03-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
| CN117295492A (zh) | 2021-05-25 | 2023-12-26 | 活跃生物技术有限公司 | 多个他喹莫德粒子及其用途 |
| JP2024524158A (ja) | 2021-07-02 | 2024-07-05 | アクティブ バイオテック エイビー | タスキニモドを含有する医薬製品および前記製品の純度を評価する方法 |
| TWI838849B (zh) * | 2021-09-13 | 2024-04-11 | 美商美國禮來大藥廠 | Ahr促效劑 |
| AR126963A1 (es) | 2021-09-13 | 2023-12-06 | Lilly Co Eli | Agonistas de ahr |
| CA3241699A1 (en) * | 2021-12-20 | 2023-06-29 | The Johns Hopkins University | Compounds for treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| GB9404378D0 (en) * | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
-
2000
- 2000-06-21 SE SE0002320A patent/SE0002320D0/xx unknown
- 2000-10-24 HK HK03100644.7A patent/HK1049830A1/zh unknown
- 2000-10-24 EP EP00973329A patent/EP1224172B1/de not_active Expired - Lifetime
- 2000-10-24 NZ NZ518296A patent/NZ518296A/xx not_active IP Right Cessation
- 2000-10-24 DK DK00973329T patent/DK1224172T3/da active
- 2000-10-24 KR KR1020027005077A patent/KR100597938B1/ko not_active Expired - Fee Related
- 2000-10-24 ES ES00973329T patent/ES2280258T3/es not_active Expired - Lifetime
- 2000-10-24 HU HU0203238A patent/HU229072B1/hu not_active IP Right Cessation
- 2000-10-24 JP JP2001533112A patent/JP3950337B2/ja not_active Expired - Fee Related
- 2000-10-24 AT AT00973329T patent/ATE358668T1/de not_active IP Right Cessation
- 2000-10-24 AU AU11851/01A patent/AU775057B2/en not_active Ceased
- 2000-10-24 KR KR1020067008739A patent/KR100674160B1/ko not_active Expired - Fee Related
- 2000-10-24 IL IL14878200A patent/IL148782A0/xx active IP Right Grant
- 2000-10-24 EE EEP200200207A patent/EE200200207A/xx unknown
- 2000-10-24 CA CA002386775A patent/CA2386775C/en not_active Expired - Fee Related
- 2000-10-24 HR HR20020353A patent/HRP20020353A2/hr not_active Application Discontinuation
- 2000-10-24 CZ CZ20021293A patent/CZ298534B6/cs not_active IP Right Cessation
- 2000-10-24 DE DE60034240T patent/DE60034240T2/de not_active Expired - Lifetime
- 2000-10-24 UA UA2002032524A patent/UA73748C2/uk unknown
- 2000-10-24 WO PCT/SE2000/002055 patent/WO2001030758A1/en not_active Ceased
-
2002
- 2002-03-20 IL IL148782A patent/IL148782A/en not_active IP Right Cessation
- 2002-04-02 IS IS6329A patent/IS2750B/is unknown
- 2002-04-24 NO NO20021932A patent/NO323320B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323320B1 (no) | Medikament egnet til behandling av ondartede tumorer | |
| US6395750B1 (en) | Drugs for the treatment of malignant tumors | |
| CA2822432C (en) | Bicyclic pkm2 activators | |
| KR20150038363A (ko) | 지방산 아미드 가수분해효소 억제제로서 보론산 및 에스테르 | |
| CN117447470A (zh) | 一种作为hpk1抑制剂的吡咯并吡啶衍生物、制备方法及其应用 | |
| TW201341386A (zh) | 唑並［１，５－ａ］嘧啶基化合物、包含其之組成物及其使用方法 | |
| CN115873018B (zh) | 苯并嘧啶和苯并三嗪类造血祖细胞激酶1降解剂及其应用 | |
| US11578058B2 (en) | Heterocyclic compounds for inhibiting TYK2 activities | |
| KR20210027382A (ko) | 접히지 않은 단백질 반응의 활성화제 | |
| US11504379B2 (en) | Amide compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same | |
| JP2020531495A (ja) | 癌治療のための組成物および方法 | |
| WO2022028429A1 (zh) | 用于根除癌症干细胞并诱导damp介导的抗肿瘤免疫反应的一组新型copi/arf1-脂解途径抑制剂和化合物 | |
| CN115521233B (zh) | 一种RORγ激动剂及其在制备治疗肿瘤疾病药物以及促进Type17细胞分化中的应用 | |
| RU2240313C2 (ru) | Лекарственные средства для лечения злокачественных опухолей | |
| CN113395968B (zh) | 用于治疗疾病的fak抑制剂和btk抑制剂的组合 | |
| EP4117660B1 (de) | Verfahren zur modulierung der t-zell-aktivierung und zur behandlung von chronischer herzinsuffizienz mit carboranen | |
| TW202034911A (zh) | 肥胖症的治療 | |
| CN107286057A (zh) | 间苯二酚类化合物及医药用途 | |
| WO2019056376A1 (zh) | 酸敏感的吉非替尼-氟硼二吡咯衍生物及其制备方法和在医药上的应用 | |
| TW202434580A (zh) | 蛋白質酪胺酸磷酸酶抑制劑、其組合物及使用方法 | |
| CN117126072A (zh) | 一种含酯链pd-1/pd-l1小分子抑制剂及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |